Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434-5

Affiliations

• ¹ Cartes d'Identité des Tumeurs (CIT) Program, Ligue Nationale Contre le Cancer, Paris, France. Electronic address: [email protected].
• ² Cartes d'Identité des Tumeurs (CIT) Program, Ligue Nationale Contre le Cancer, Paris, France.
• ³ Department of Pathology, Institut Curie, Saint-Cloud, France; Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France.
• ⁴ Division of Urological Research, Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.
• ⁵ Canada's Michael Smith Genome Sciences Center, BC Cancer Agency, Vancouver, BC, Canada.
• ⁶ Department of Urology, Bern University Hospital, Bern, Switzerland.
• ⁷ Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
• ⁸ Cartes d'Identité des Tumeurs (CIT) Program, Ligue Nationale Contre le Cancer, Paris, France; Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France; Bioinformatics and Systems Biology Laboratory, Federal University of Paraná, Polytechnic Center, Curitiba, Brazil.
• ⁹ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ¹⁰ Johns Hopkins Greenberg Bladder Cancer Institute and Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA.
• ¹¹ Bioinformatics and Systems Biology Laboratory, Federal University of Paraná, Polytechnic Center, Curitiba, Brazil.
• ¹² Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
• ¹³ Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
• ¹⁴ Division of Urology, Department of Surgery, University of Toronto, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada.
• ¹⁵ Institute of Pathology, University Erlangen-Nürnberg, Erlangen, Germany.
• ¹⁶ Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ¹⁷ Bladder Cancer Center, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA.
• ¹⁸ Barts Cancer Institute ECMC, Barts Health and the Royal Free NHS Trust, Queen Mary University of London, London, UK.
• ¹⁹ Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), CIBERONC, Madrid, Spain.
• ²⁰ Cedars-Sinai Samuel Oschin Cancer Institute, Los Angeles, CA, USA.
• ²¹ Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
• ²² Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
• ²³ Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
• ²⁴ Scott Department of Urology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA.
• ²⁵ Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO), CIBERONC, Madrid, Spain.
• ²⁶ Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France.
• ²⁷ Division of Molecular Hematology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden.
• ²⁸ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ²⁹ GenomeDx Biosciences Inc., Vancouver, BC, Canada.
• ³⁰ Broad Institute of MIT and Harvard, Cambridge, MA, USA.
• ³¹ Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
• ³² Department of Urology, University of Versailles-Saint-Quentin-en-Yvelines, Foch Hospital, Suresnes, France.
• ³³ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ³⁴ Department of Pathology, Institut Curie Hospital Group, Paris, France.
• ³⁵ Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.